Literature DB >> 23614796

Methylation status regulates lipoprotein lipase expression in chronic lymphocytic leukemia.

Cecilia Abreu1, Pilar Moreno, Florencia Palacios, Mercedes Borge, Pablo Morande, Ana Inés Landoni, Raul Gabus, Guillermo Dighiero, Mirta Giordano, Romina Gamberale, Pablo Oppezzo.   

Abstract

Among different prognostic factors in chronic lymphocytic leukemia (CLL), we previously demonstrated that lipoprotein lipase (LPL) is associated with an unmutated immunoglobulin profile and clinical poor outcome. Despite the usefulness of LPL for CLL prognosis, its functional role and the molecular mechanism regulating its expression are still open questions. Interaction of CLL B-cells with the tissue microenvironment favors disease progression by promoting malignant B-cell growth. Since tissue methylation can be altered by environmental factors, we investigated the methylation status of the LPL gene and the possibility that overexpression could be associated with microenvironment signals. Our results show that a demethylated state of the LPL gene is responsible for its anomalous expression in unmutated CLL cases and that this expression is dependent on microenvironment signals. Overall, this work proposes that an epigenetic mechanism, triggered by the microenvironment, regulates LPL expression in CLL disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23614796     DOI: 10.3109/10428194.2013.796057

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2.

Authors:  Sujata Bhoi; Viktor Ljungström; Panagiotis Baliakas; Mattias Mattsson; Karin E Smedby; Gunnar Juliusson; Richard Rosenquist; Larry Mansouri
Journal:  Epigenetics       Date:  2016-04-29       Impact factor: 4.528

2.  Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Alessandra Ferrajoli; Jan Burger; Phillip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2018-02-21

3.  Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.

Authors:  Uri Rozovski; Srdana Grgurevic; Carlos Bueso-Ramos; David M Harris; Ping Li; Zhiming Liu; Ji Yuan Wu; Preetesh Jain; William Wierda; Jan Burger; Susan O'Brien; Nitin Jain; Alessandra Ferrajoli; Michael J Keating; Zeev Estrov
Journal:  Mol Cancer Res       Date:  2015-03-02       Impact factor: 5.852

4.  Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion.

Authors:  Cristina Bagacean; Christelle Le Dantec; Christian Berthou; Adrian Tempescul; Hussam Saad; Anne Bordron; Mihnea Zdrenghea; Victor Cristea; Nathalie Douet-Guilbert; Yves Renaudineau
Journal:  Clin Epigenetics       Date:  2017-11-28       Impact factor: 6.551

Review 5.  Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia: New Insights into Leukemic Progression.

Authors:  Daniel Prieto; Pablo Oppezzo
Journal:  Molecules       Date:  2017-12-05       Impact factor: 4.411

6.  BjussuLAAO-II induces cytotoxicity and alters DNA methylation of cell-cycle genes in monocultured/co-cultured HepG2 cells.

Authors:  Ana Rita Thomazela Machado; Alexandre Ferro Aissa; Diego Luis Ribeiro; Rui Seabra Ferreira; Suely Vilela Sampaio; Lusânia Maria Greggi Antunes
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2019-03-11

Review 7.  Targeting metabolic reprogramming in chronic lymphocytic leukemia.

Authors:  Yu Nie; Xiaoya Yun; Ya Zhang; Xin Wang
Journal:  Exp Hematol Oncol       Date:  2022-06-27

Review 8.  Aberrant Promoter Hypomethylation in CLL: Does It Matter for Disease Development?

Authors:  Garland Michael Upchurch; Staci L Haney; Rene Opavsky
Journal:  Front Oncol       Date:  2016-08-11       Impact factor: 6.244

9.  Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.

Authors:  P-P Liu; J Liu; W-Q Jiang; J S Carew; M A Ogasawara; H Pelicano; C M Croce; Z Estrov; R-H Xu; M J Keating; P Huang
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.